PP
ALXN

PDT Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

PDT Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,104
Closed -$1.89M – 941
2020
Q4 		$1.89M Sell
12,104
-43,647
-78% -$5.61M 0.13% 252
2020
Q3 		$6.38M Sell
55,751
-11,889
-18% -$1.28M 0.42% 87
2020
Q2 		$7.59M Sell
67,640
-41,519
-38% -$4.41M 0.52% 62
2020
Q1 		$9.8M Buy
109,159
+25,028
+30% +$2.46M 0.78% 11
2019
Q4 		$9.1M Buy
+84,131
New +$9M 0.56% 62
2019
Q3 		– Sell
-79,500
Closed -$10.4M – 499
2019
Q2 		$10.4M Hold
79,500
– – 0.62% 36
2019
Q1 		$10.7M Sell
79,500
-37
-0% -$4.6K 0.61% 37
2018
Q4 		$7.74M Buy
79,537
+25
+0% +$2.96K 0.43% 87
2018
Q3 		$11.1M Buy
+79,512
New +$9.97M 0.46% 60
2015
Q4 		– Sell
-60,440
Closed -$9.45M – 1076
2015
Q3 		$9.45M Buy
+60,440
New +$11M 0.21% 127
2015
Q2 		– Sell
-60,173
Closed -$10.4M – 1742
2015
Q1 		$10.4M Buy
60,173
+55,473
+1,180% +$10M 0.26% 86
2014
Q4 		$870K Sell
4,700
-1,000
-18% -$185K 0.08% 358
2014
Q3 		$945K Sell
5,700
-72,131
-93% -$11.8M 0.02% 674
2014
Q2 		$12.2M Sell
77,831
-82,559
-51% -$13M 0.32% 57
2014
Q1 		$24.4M Buy
160,390
+158,271
+7,469% +$25.2M 0.59% 22
2013
Q4 		$282K Sell
2,119
-20,316
-91% -$2.44M 0.03% 537
2013
Q3 		$2.61M Sell
22,435
-90,724
-80% -$9.95M 0.07% 385
2013
Q2 		$10.4M Buy
+113,159
New +$10.9M 0.26% 78

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PDT Partners's ALXN Position: Q1 2021 in Review

PDT Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 12,104 shares — an estimated $1.89M sold.

PDT Partners first reported a position in ALXN in Q2 2013 and held it in 18 quarters. The position peaked at $24.4M in Q1 2014. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • PDT Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • PDT Partners sold 12,104 Alexion Pharmaceuticals shares in Q1 2021, an estimated $1.89M.
  • PDT Partners first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • PDT Partners's Alexion Pharmaceuticals position peaked at $24.4M in Q1 2014.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on PDT Partners's 13F filing for Q1 2021, filed 17 May 2021.